Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CM336 Injection, Standard Of Care( SOC).
- Who it may be relevant to
- Registry conditions: Multiple Myeloma (MM). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase III, Randomized, Open-Label, Multicenter Study Comparing CM336 Monotherapy vs. Investigators Selected Standard of Care in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received ≥2 Prior Lines of Therapy
Overview
The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.
Interventions
- Drug CM336 Injection
Specified dose on specified days - Drug Standard Of Care( SOC)
Specified dose on specified days
Primary outcome measures
- PFS [Time frame: Up to 4 years]
Eligibility criteria
Inclusion criteria
- The subjects voluntarily sign the informed consent form (ICF) and agree to abide by the provisions of this protocol.
- Age ≥ 18 years old, gender is not limited.
- Eastern Cooperative Oncology Group performance status score (ECOG) 0-2 points.
- Patients with relapsed or refractory multiple myeloma who have received at least two lines of anti-myeloma treatment previously, and must include at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-Cluster of Differentiation 38(CD38) monoclonal antibody.
- The subject has evidence of disease progression or has not achieved remission after the last line of treatment, as determined by the investigator based on the International Myeloma Working Group (2016) criteria.
- The subject has measurable disease at the screening period, meeting at least one of the following criteria:
- Serum M protein ≥ 5 g/L;
- Urinary M protein ≥ 200 mg/24 h;
- Serum free light chain (sFLC) ≥ 100 mg/L and abnormal κ/ λ ratio.
Exclusion criteria
- Previous receipt of any treatment targeting B-cell maturation antigen (BCMA).
- Those who are intolerant to dexamethasone will be excluded.
- Within 3 months prior to the first administration, they have received chimeric antigen receptor T cells (CAR-T) /chimeric antigen receptor Nature killer cell (CAR-NK) therapy.
- Within 3 months prior to the first administration, they have received autologous stem cell transplantation; within 6 months prior to the first administration, they have received allogeneic stem cell transplantation (for subjects who have received allogeneic transplantation, they must have discontinued all immunosuppressants for ≥ 6 weeks and have no signs of graft-versus-host disease before being eligible for enrollment).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Institute of Hematology & Blood Diseases Hospital — Tianjin
Identifiers
NCT: NCT07181239 · CM336-021209